Your browser doesn't support javascript.
loading
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.
Ferro, Matteo; Baba, Dragos-Florin; de Cobelli, Ottavio; Musi, Gennaro; Lucarelli, Giuseppe; Terracciano, Daniela; Porreca, Angelo; Busetto, Gian Maria; Del Giudice, Francesco; Soria, Francesco; Gontero, Paolo; Cantiello, Francesco; Damiano, Rocco; Rocco, Papalia; Scarpa, Roberto Mario; Abu Farhan, Abdal Rahman; Autorino, Riccardo; Brescia, Antonio; Marchioni, Michele; Mari, Andrea; Minervini, Andrea; Longo, Nicola; Chiancone, Francesco; Perdona', Sisto; Barone, Biagio; Placido, Pietro De; Catellani, Michele; Bottero, Danilo; Ditonno, Pasquale; Battaglia, Michele; Zamboni, Stefania; Antonelli, Alessandro; Greco, Francesco; Russo, Giorgio Ivan; Smelzo, Salvatore; Hurle, Rodolfo; Crisan, Nicolae; Manfredi, Matteo; Porpiglia, Francesco; Crocetto, Felice; Buonerba, Carlo; Danilesco, Alina; Vartolomei, Mihai Dorin.
Afiliação
  • Ferro M; Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
  • Baba DF; Department of Cell & Molecular Biology, University of Medicine and Pharmacy, Targu Mures, Romania.
  • de Cobelli O; Cardiovascular Disease and Transplant Institute, Department of Urology, Targu Mures, Romania.
  • Musi G; Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
  • Lucarelli G; Department of Oncology & Haematology-Oncology, University of Milan, Milan, Italy.
  • Terracciano D; Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
  • Porreca A; Department of Oncology & Haematology-Oncology, University of Milan, Milan, Italy.
  • Busetto GM; Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy.
  • Del Giudice F; Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
  • Soria F; Department of Oncological Urology, Veneto Institute of Oncology IOV, IRCSS, Padua, Italy.
  • Gontero P; Department of Urology, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy.
  • Cantiello F; Department of Urology, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy.
  • Damiano R; Division of Urology, Department of Surgical Sciences, AOU Citta´ della Salute e della Scienza, Turin School of Medicine, Turin, Italy.
  • Rocco P; Division of Urology, Department of Surgical Sciences, AOU Citta´ della Salute e della Scienza, Turin School of Medicine, Turin, Italy.
  • Scarpa RM; Department of Urology, University of Catanzaro, Università 'Magna Græcia', Catanzaro, Italy.
  • Abu Farhan AR; Department of Urology, University of Catanzaro, Università 'Magna Græcia', Catanzaro, Italy.
  • Autorino R; Department of Urology, Policlinic University Campus of Bio-Medicine of Rome, Rome, Italy.
  • Brescia A; Department of Urology, Policlinic University Campus of Bio-Medicine of Rome, Rome, Italy.
  • Marchioni M; Department of Urology, University of Catanzaro, Università 'Magna Græcia', Catanzaro, Italy.
  • Mari A; Division of Urology, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
  • Minervini A; Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
  • Longo N; Department of Medical, Oral & Biotechnological Sciences, Gabriele d'Annunzio University of Chieti & Pescara, Chieti, Italy.
  • Chiancone F; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy.
  • Perdona' S; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy.
  • Barone B; Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy.
  • Placido P; Urology Unit, AORN Cardarelli, Naples, Italy.
  • Catellani M; Division of Urology, National Cancer Institute IRCCS Pascale Foundation, Naples, Italy.
  • Bottero D; Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy.
  • Ditonno P; Department of Clinical Medicine & Surgery, University of Naples Federico II, Naples, Italy.
  • Battaglia M; Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
  • Zamboni S; Department of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
  • Antonelli A; Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy.
  • Greco F; Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy.
  • Russo GI; Department of Urology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Smelzo S; Department of Urology, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Hurle R; Department of Urology, University of Verona, Verona, Italy.
  • Crisan N; Clinic of Urology, Centro Salute Uomo, Bergamo, Italy.
  • Manfredi M; Department of Urology, University of Catania, Catania, Italy.
  • Porpiglia F; Department of Urology, San Raffaele Turro Hospital, San Raffaele University, Milan, Italy.
  • Crocetto F; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Buonerba C; Department of Urology, University of Medicine & Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.
  • Danilesco A; Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy.
  • Vartolomei MD; Urology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy.
Future Sci OA ; 7(7): FSO709, 2021 Aug.
Article em En | MEDLINE | ID: mdl-34258022
ABSTRACT

AIM:

To investigate the prognostic role of neutrophil percentage-to-albumin ratio (NPAR) in muscle-invasive bladder cancer (MIBC) patients treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). PATIENTS &

METHODS:

213 patients were included. INCLUSION CRITERIA Nonmetastatic, MIBC (cT2-T4aN0M0), at least three cycles of NAC, undergone RC and with blood count within 30 days before NAC.

RESULTS:

Five-years overall survival (OS) with NPAR >18 was 34.06% (95% CI 18.3-50.5) and 65.37% (95% CI 52.4-75.6) with NPAR <18. Five years cancer-specific survival (CSS) with NPAR >18 was 42.9% (95% CI 23.9-60.7) and 74.5% (95% CI 62.6-83.1) with NPAR <18 (p < 0.001). In multivariable analysis, NPAR increased OS of 1.3 points and CSS of 4.37 points.

CONCLUSION:

High NPAR prior to NAC seems to be a strong predictor of OS and CSS in MIBC patients treated with NAC and RC.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Future Sci OA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Future Sci OA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália